Modern look on resistance to platinum in patients with the serous ovarian cancer

Rybin, A. I.; Kuznetsova, O. V.

dc.contributor.author	Rybin, A. I.
dc.contributor.author	Kuznetsova, O. V.
dc.date.accessioned	2026-02-24T07:56:00Z
dc.date.available	2026-02-24T07:56:00Z
dc.date.issued	2025
dc.identifier.citation	Rybin, A. I., Kuznetsova, O. V. Modern look on resistance to platinum in patients with the serous ovarian cancer // SWorldJournal. 2025. Part. 2, n. 33. P. 130–137.	uk_UA
dc.identifier.uri	https://repo.odmu.edu.ua:443/xmlui/handle/123456789/19169
dc.description.abstract	The study was aimed to determine the platinum-resistance biomarkers in patients with ovarian cancer. 29 platinum-resistant patients with verified serous ovarian cancer of IIIA–IIIC stages were examined, who received 6 courses of adjuvant chemotherapy with platinum preparations (cisplatin 75–100 mg/m2 intravenously with hydration and forced diuresis every 3 weeks) in the postoperative period. As control, 26 patients with non-recurrence of the disease performed for 6 months post-treatment observation (platinum-susceptible tumors) were observed. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter.	uk_UA
dc.language.iso	en	uk_UA
dc.subject	ovarian cancer	uk_UA
dc.subject	treatment	uk_UA
dc.subject	platitum resistance	uk_UA
dc.subject	biomarkers	uk_UA
dc.title	Modern look on resistance to platinum in patients with the serous ovarian cancer	uk_UA
dc.type	Article	uk_UA